Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade
Filed with ASX · · 4 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- CMS proposes payment improvement for radiopharma diagnostics
- Telix Elects to Withdraw from Proposed U.S. Listing
- Trading Halt
- Telix Launches Proposed US IPO
- Telix Completes TLX250-CDx (Zircaix) BLA Submission
Later from Telix Pharmaceuticals
- Telix Announces A$600 Million Convertible Bonds Offering
- Telix Successfully Prices A$650M Convertible Bonds
- Convertible Bond Cleansing Notice
- Telix Completes A$650 Million of Convertible Bonds
- Telix 1H 2024 Appendix 4D and Interim Report
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals